比梅基祖马布:在西班牙安达卢西亚的实际临床实践中短期有效性和安全性
Ricardo Ruiz-Villaverde1,2, Lourdes Rodriguez-Fernandez-Freire3, Marta Cebolla-Verdugo1,2
1Hospital Universitario San Cecilio, 18016 Granada, Spain.
Life (Basel, Switzerland)
|March 28, 2024
概括
比梅基祖马布 (BMK) 在现实环境中有效治疗中度至严重的斑块性牛皮,显示快速和持续的皮肤清除和改善生活质量,没有安全问题. 这项研究证实了BMK的说法.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮是一种慢性炎症性皮肤疾病,影响全球人口的2-10%.
- 针对IL-17A和IL-17F的单克隆抗体比梅奇祖马布 (BMK) 已被批准用于中度至重度的斑块性牛皮.
- 现实世界的证据对于评估临床试验之外的治疗有效性至关重要.
研究的目的:
- 评估比梅奇祖马布 (BMK) 在中度至重度斑块性牛皮患者的疗效和安全性.
- 在以前未接受过治疗的患者群体和不耐药患者群体中评估BMK.
- 在现实世界,多中心观测环境中分析结果.
主要方法:
- 在安达卢西亚五家医院接受BMK治疗的22名患者的回顾性分析.
- 从2023年4月到2023年2月收集的数据.
- 关键结果措施包括PASI,BSA,VAS,DLQI和MDA在多个时间点到24周.
主要成果:
- 到第16周,在PASI,BSA,DLQI和的得分中观察到显著的改善.
- 95.4%的患者在第16周达到最低疾病活性 (MDA).
- 没有报告与治疗相关的安全问题或停止治疗.
结论:
- 比梅基祖马布在现实环境中证明了治疗中度至重度斑块性牛皮的最佳疗效和安全性.
- BMK提供快速和持续的牛皮清除,提高患者的生活质量.
- 需要对更大的样本大小进行进一步的研究,并专注于患者报告的结果.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...